Antitransforming growth factor-β therapy in fibrosis: recent progress and implications for systemic sclerosis
Anti-TGF-β therapies promise to have a major impact in systemic sclerosis. Significant
concerns regarding efficacy and safety need to be addresed. The identification of optimal
candidates for therapy, and of biomarkers of safety and efficacy, are critical challenges
ahead.
concerns regarding efficacy and safety need to be addresed. The identification of optimal
candidates for therapy, and of biomarkers of safety and efficacy, are critical challenges
ahead.
Summary
Anti-TGF-β therapies promise to have a major impact in systemic sclerosis. Significant concerns regarding efficacy and safety need to be addresed. The identification of optimal candidates for therapy, and of biomarkers of safety and efficacy, are critical challenges ahead.
Lippincott Williams & Wilkins